Find latest Myelofibrosis (MF) videos · 100+ videos
XV Eurasian Hematology-Oncology Congress - EHOC 2024
Avatar

Current and Future Treatment Landscape of Myelofibrosis

By XV Eurasian Hematology-Oncology Congress - EHOC 2024 FEATURING Rami Komrokji
By XV Eurasian Hematology-Oncology Congress - EHOC 2024 FEATURING Rami Komrokji
179 views
October 8, 2024
Comments 0
Login to view comments. Click here to Login

Featured Video

07:44
Incyte

Optimizing the Management of Patients with Polycythemia Vera (PV)

Feat. P. Bose, R. Rampal

Featured Video

11:12
Stemline

A proven CD123 targeted therapy for BPDCN

Feat. H. Erba

Related Videos

Penn Medicine Abramson Cancer Center

2025 Breast Cancer Highlights from International Medical Meetings: 5…

Thu, Mar 6, 2025
Total Health

2025 West Oncology Conference

Sat, Feb 8, 2025
19:57

New

ASH 2024 Summary: MPN Highlights and Clinical Implications

2024 ASH Annual Meeting Insights Hub

D. Tremblay

297 views
24:08

Evaluation, Diagnosis, Prognostication, and Emerging Therapies for M…

Indy Hematology Review

A. Tefferi

1.5K views
24:35

Current Approaches in the Treatment of Myeloproliferative Neoplasms

Indy Hematology Review

A. Tefferi

1.4K views
14:01

ESMO 2024 Summary: Highlights in Heme Malignancies

2024 ESMO Annual Meeting Insights Hub

M. Gomes da Silva

488 views
10:01

New

ASH 2024 Summary: Pegylated Interferon in MPN - The Who, Why, and How

2024 ASH Annual Meeting Insights Hub

J. Kiladjian

137 views
25:44

Myeloid Malignancies: Hot Topics in 2024

Yale Cancer Center

N. Podoltsev

301 views
21:38

Allele Burden in MPN: Practical Considerations

16th International Congress on Myeloproliferative Neoplasms

R. Rampal

159 views
15:43
Incyte

Importance of Early Management of Patients with Myelofibrosis (MF)

Feat. P. Bose, R. Rampal
16:51
Incyte

Effects of PV Treatment on White Blood Cell Count and Thrombotic Risk

Feat. C. Harrison
20:54

Novel Agents for MPNs in 2024

16th International Congress on Myeloproliferative Neoplasms

N. Pemmaraju

121 views
05:46

New

ASH 2024 Insights: Updated Ph3 MANIFEST-2 Results - Pelabresib + Rux…

2024 ASH Annual Meeting Insights Hub

J. Mascarenhas

74 views
18:07

Selection of JAK1/2 Inhibitors for Primary Myelofibrosis

16th International Congress on Myeloproliferative Neoplasms

A. Gerds

89 views
16:26
Incyte

Effects of a Treatment Option on Hematocrit Control and Spleen Volum…

Feat. C. Harrison
06:18

SIMPLIFY-2 Trial: Momelotinib Vs. Continued Ruxolitinib or Best Avai…

Cleveland Clinic Taussig Cancer Institute

A. Gerds

308 views
35:48

Experts Discuss How They Choose 2L Therapy in MF

MyCancerHaven

R. Vij, P. Bose

164 views
17:23

Management of MF After Ruxolitinib Failure

Vanderbilt University Medical Center (VUMC)

A. Kishtagari

204 views
04:51

New

ASH 2024 Summary: Survival Outcomes in Patients With MF & New or Wor…

2024 ASH Annual Meeting Insights Hub

A. Kuykendall

51 views
08:06

Current Management of Accelerated/Blast-Phase MPNs

UChicago Medicine

A. Patel

76 views
30:03

Experts Discuss Their Current Approach to Treating MF

MyCancerHaven

R. Vij, A. Yacoub

129 views
07:00

Approach to Selecting Treatment for Myelofibrosis in 2024

GRACE

A. Srisuwananukorn

46 views
AUTOPLAY